Discovery of D25, a Potent and Selective MNK Inhibitor for Sepsis-Associated Acute Spleen Injury
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Qiang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Sepsis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Themen: Sepsis
Abstract (Originalsprache)
Mitogen-activated protein kinase-interacting protein kinases (MNKs) and phosphorylate eukaryotic initiation factor 4E (p-eIF4E) play a critical role in regulating mRNA translation and protein synthesis associated with the development of cancer, metabolism, and inflammation. This study undertakes the modification of a 4-(3-(piperidin-4-yl)-1H-pyrazol-5-yl)pyridine structure, leading to the discovery of 4-(3-(piperidin-4-yl)-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridine (D25) as a potent and selective MNK inhibitor. D25 demonstrated inhibitory activity, with IC50 values of 120.6 nM for MNK1 and 134.7 nM for MNK2, showing exceptional selectivity. D25 inhibited the expression of pro-inflammation cytokines in RAW264.7 cells, such as inducible NO synthase, cyclooxygenase-2, and interleukin-6 (IL-6). In the lipopolysaccharide-induced sepsis mouse model, D25 significantly reduced p-eIF4E in spleen tissue and decreased the expression of tumor necrosis factor α, interleukin-1β, and IL-6, and it also reduced the production of reactive oxygen species, resulting in improved organ injury caused by inflammation. This suggests that D25 may provide a potential treatment for sepsis and sepsis-associated acute spleen injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
- Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China.
- Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, and School of Pharmacy, Guangdong Medical University, Zhanjiang 524023, China.
- School of Pharmacy, Yantai University, Yantai 264005, China.
- School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- School of Medicine, Shanghai University, Shanghai 200444, China.
ORCID-Profile: Rilei Yu, Tao Jiang, Yue-Wei Guo
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Shandong Laboratory Program
Zitieren
APA
Li, Q., Ke, L., Yu, D., Xu, H., Zhang, Z., Yu, R., Jiang, T., Guo, Y. W., Su, M., & Jin, X. (2024). Discovery of D25, a Potent and Selective MNK Inhibitor for Sepsis-Associated Acute Spleen Injury. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02441
Vancouver
Li Q, Ke L, Yu D, Xu H, Zhang Z, Yu R, et al. Discovery of D25, a Potent and Selective MNK Inhibitor for Sepsis-Associated Acute Spleen Injury. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02441
BibTeX
@article{Li2024,
author = {Li, Qiang and Ke, Linmao and Yu, Dandan and Xu, Han and Zhang, Zixuan and Yu, Rilei and Jiang, Tao and Guo, Yue-Wei and Su, Mingzhi and Jin, Xin},
title = {Discovery of D25, a Potent and Selective MNK Inhibitor for Sepsis-Associated Acute Spleen Injury},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02441}
}
EUVIMED